COVID-19 疫苗可有效预防医护人员的无症状感染和严重感染:临床回顾

IF 2.7 Q3 IMMUNOLOGY Vaccine: X Pub Date : 2024-08-05 DOI:10.1016/j.jvacx.2024.100546
Oliver Galgut , Fiona Ashford , Alexandra Deeks , Andeep Ghataure , Mimia Islam , Tanvir Sambhi , Yiu Wayn Ker , Christopher J.A. Duncan , Thushan I. de Silva , Susan Hopkins , Victoria Hall , Paul Klenerman , Susanna Dunachie , Alex Richter
{"title":"COVID-19 疫苗可有效预防医护人员的无症状感染和严重感染:临床回顾","authors":"Oliver Galgut ,&nbsp;Fiona Ashford ,&nbsp;Alexandra Deeks ,&nbsp;Andeep Ghataure ,&nbsp;Mimia Islam ,&nbsp;Tanvir Sambhi ,&nbsp;Yiu Wayn Ker ,&nbsp;Christopher J.A. Duncan ,&nbsp;Thushan I. de Silva ,&nbsp;Susan Hopkins ,&nbsp;Victoria Hall ,&nbsp;Paul Klenerman ,&nbsp;Susanna Dunachie ,&nbsp;Alex Richter","doi":"10.1016/j.jvacx.2024.100546","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Health care workers (HCWs) have been at increased risk of infection during the SARS-CoV-2 pandemic and as essential workers have been prioritised for vaccination. Due to increased exposure HCW are considered a predictor of what might happen in the general population, particularly working age adults. This study aims to summarise effect of vaccination in this ‘at risk’ cohort.</p></div><div><h3>Methods</h3><p>Ovid MEDLINE and Embase were searched, and 358 individual articles were identified. Of these 49 met the inclusion criteria for review and 14 were included in a meta-analysis.</p></div><div><h3>Results</h3><p>Participants included were predominantly female and working age. Median time to infection was 51 days. Reported vaccine effectiveness against infection, symptomatic infection, and infection requiring hospitalisation were between 5 and 100 %, 34 and 100 %, and 65 and 100 % (respectively). No vaccinated HCW deaths were recorded in any study. Pooled estimates of protection against infection, symptomatic infection, and hospitalisation were, respectively, 84.7 % (95 % CI 72.6–91.5 %, <em>p</em> &lt; 0.0001), 86.0 % (95 % CI 67.2 %-94.0 %; p &lt; 0.0001), and 96.1 % (95 % CI 90.4 %-98.4 %). Waning protection against infection was reported by four studies, although protection against hospitalisation for severe infection persists for at least 6 months post vaccination.</p></div><div><h3>Conclusions</h3><p>Vaccination against SARS-CoV2 in HCWs is protective against infection, symptomatic infection, and hospitalisation. Waning protection is reported but this awaits more mature studies to understand durability more clearly. This study is limited by varying non-pharmacological responses to COVID-19 between included studies, a predominantly female and working age population, and limited information on asymptomatic transmission or long COVID protection.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100546"},"PeriodicalIF":2.7000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001190/pdfft?md5=1f7b30485082d7dbf6452ef88042fb7f&pid=1-s2.0-S2590136224001190-main.pdf","citationCount":"0","resultStr":"{\"title\":\"COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review\",\"authors\":\"Oliver Galgut ,&nbsp;Fiona Ashford ,&nbsp;Alexandra Deeks ,&nbsp;Andeep Ghataure ,&nbsp;Mimia Islam ,&nbsp;Tanvir Sambhi ,&nbsp;Yiu Wayn Ker ,&nbsp;Christopher J.A. Duncan ,&nbsp;Thushan I. de Silva ,&nbsp;Susan Hopkins ,&nbsp;Victoria Hall ,&nbsp;Paul Klenerman ,&nbsp;Susanna Dunachie ,&nbsp;Alex Richter\",\"doi\":\"10.1016/j.jvacx.2024.100546\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Health care workers (HCWs) have been at increased risk of infection during the SARS-CoV-2 pandemic and as essential workers have been prioritised for vaccination. Due to increased exposure HCW are considered a predictor of what might happen in the general population, particularly working age adults. This study aims to summarise effect of vaccination in this ‘at risk’ cohort.</p></div><div><h3>Methods</h3><p>Ovid MEDLINE and Embase were searched, and 358 individual articles were identified. Of these 49 met the inclusion criteria for review and 14 were included in a meta-analysis.</p></div><div><h3>Results</h3><p>Participants included were predominantly female and working age. Median time to infection was 51 days. Reported vaccine effectiveness against infection, symptomatic infection, and infection requiring hospitalisation were between 5 and 100 %, 34 and 100 %, and 65 and 100 % (respectively). No vaccinated HCW deaths were recorded in any study. Pooled estimates of protection against infection, symptomatic infection, and hospitalisation were, respectively, 84.7 % (95 % CI 72.6–91.5 %, <em>p</em> &lt; 0.0001), 86.0 % (95 % CI 67.2 %-94.0 %; p &lt; 0.0001), and 96.1 % (95 % CI 90.4 %-98.4 %). Waning protection against infection was reported by four studies, although protection against hospitalisation for severe infection persists for at least 6 months post vaccination.</p></div><div><h3>Conclusions</h3><p>Vaccination against SARS-CoV2 in HCWs is protective against infection, symptomatic infection, and hospitalisation. Waning protection is reported but this awaits more mature studies to understand durability more clearly. This study is limited by varying non-pharmacological responses to COVID-19 between included studies, a predominantly female and working age population, and limited information on asymptomatic transmission or long COVID protection.</p></div>\",\"PeriodicalId\":43021,\"journal\":{\"name\":\"Vaccine: X\",\"volume\":\"20 \",\"pages\":\"Article 100546\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590136224001190/pdfft?md5=1f7b30485082d7dbf6452ef88042fb7f&pid=1-s2.0-S2590136224001190-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine: X\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590136224001190\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590136224001190","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言在 SARS-CoV-2 大流行期间,医护人员(HCWs)的感染风险增加,作为基本工作者,他们被优先考虑接种疫苗。由于医护人员的接触机会增加,他们被认为是普通人群(尤其是工作年龄的成年人)中可能发生的情况的预测者。本研究旨在总结在这一 "高危 "人群中接种疫苗的效果。其中 49 篇符合审查纳入标准,14 篇被纳入荟萃分析。感染时间中位数为 51 天。据报告,疫苗对感染、无症状感染和需要住院治疗的感染的有效率分别为 5%-100%、34%-100% 和 65%-100%。在所有研究中都没有发现接种过疫苗的高危工人死亡的记录。对感染、无症状感染和住院的保护率汇总估计分别为 84.7 %(95 % CI 72.6-91.5 %,p < 0.0001)、86.0 %(95 % CI 67.2 %-94.0 %;p < 0.0001)和 96.1 %(95 % CI 90.4 %-98.4 %)。有四项研究报告称,对感染的保护作用正在减弱,但对严重感染住院的保护作用在接种疫苗后至少 6 个月内仍然存在。据报道,保护作用正在减弱,但这有待于更成熟的研究来更清楚地了解持久性。这项研究的局限性在于:纳入研究的人群对 COVID-19 的非药物反应各不相同;研究对象主要为女性和工作年龄人群;关于无症状传播或 COVID 长期保护的信息有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review

Introduction

Health care workers (HCWs) have been at increased risk of infection during the SARS-CoV-2 pandemic and as essential workers have been prioritised for vaccination. Due to increased exposure HCW are considered a predictor of what might happen in the general population, particularly working age adults. This study aims to summarise effect of vaccination in this ‘at risk’ cohort.

Methods

Ovid MEDLINE and Embase were searched, and 358 individual articles were identified. Of these 49 met the inclusion criteria for review and 14 were included in a meta-analysis.

Results

Participants included were predominantly female and working age. Median time to infection was 51 days. Reported vaccine effectiveness against infection, symptomatic infection, and infection requiring hospitalisation were between 5 and 100 %, 34 and 100 %, and 65 and 100 % (respectively). No vaccinated HCW deaths were recorded in any study. Pooled estimates of protection against infection, symptomatic infection, and hospitalisation were, respectively, 84.7 % (95 % CI 72.6–91.5 %, p < 0.0001), 86.0 % (95 % CI 67.2 %-94.0 %; p < 0.0001), and 96.1 % (95 % CI 90.4 %-98.4 %). Waning protection against infection was reported by four studies, although protection against hospitalisation for severe infection persists for at least 6 months post vaccination.

Conclusions

Vaccination against SARS-CoV2 in HCWs is protective against infection, symptomatic infection, and hospitalisation. Waning protection is reported but this awaits more mature studies to understand durability more clearly. This study is limited by varying non-pharmacological responses to COVID-19 between included studies, a predominantly female and working age population, and limited information on asymptomatic transmission or long COVID protection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vaccine: X
Vaccine: X Multiple-
CiteScore
2.80
自引率
2.60%
发文量
102
审稿时长
13 weeks
期刊最新文献
Cost of the typhoid conjugate vaccine introduction through an integrated campaign and follow-on routine immunization in Malawi The cost-effectiveness of COVID-19 vaccination program among age-groups children, adults, and elderly in Europe: A systematic review COVID-19 vaccine or booster uptake and hesitancy for children aged 6 months–5 years in the United States: A national descriptive study using the household pulse survey between March and May 2023 Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study Lot quality assurance sampling for coverage evaluation of a new vaccine: A pilot study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1